(Q38001913)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

The genetic architecture of multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Brian A. Walker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Faith E Davies

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

12 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

335-348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22495321%20AND%20SRC:MED&resulttype=core&format=json

International staging system for multiple myeloma

28 January 2020

cites work

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

31 March 2020

1 reference

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

31 March 2020

1 reference

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

31 March 2020

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

31 March 2020

1 reference

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

31 March 2020

1 reference

31 March 2020

1 reference

Initial genome sequencing and analysis of multiple myeloma

31 March 2020

1 reference

Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

31 March 2020

1 reference

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

31 March 2020

1 reference

Plasma cell differentiation requires the transcription factor XBP-1

31 March 2020

1 reference

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

31 March 2020

1 reference

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation

31 March 2020

1 reference

Untangling the unfolded protein response

31 March 2020

1 reference

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

31 March 2020

1 reference

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

31 March 2020

1 reference

Plasma cell development and survival.

31 March 2020

1 reference

Competence and competition: the challenge of becoming a long-lived plasma cell

31 March 2020

1 reference

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context

31 March 2020

1 reference

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

31 March 2020

1 reference

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

31 March 2020

1 reference

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

31 March 2020

1 reference

High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH

31 March 2020

1 reference

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

31 March 2020

1 reference

Genetic variegation of clonal architecture and propagating cells in leukaemia

31 March 2020

1 reference

Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma

31 March 2020

1 reference

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma

31 March 2020

1 reference

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms

31 March 2020

1 reference

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

31 March 2020

1 reference

Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

31 March 2020

1 reference

Familial risks and temporal incidence trends of multiple myeloma

31 March 2020

1 reference

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

31 March 2020

1 reference

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

31 March 2020

1 reference

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

31 March 2020

1 reference

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

31 March 2020

1 reference

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

31 March 2020

1 reference

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

31 March 2020

1 reference

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

31 March 2020

1 reference

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

31 March 2020

1 reference

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

31 March 2020

1 reference

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

31 March 2020

1 reference

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

31 March 2020

1 reference

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

31 March 2020

1 reference

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

31 March 2020

1 reference

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

31 March 2020

1 reference

Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma

31 March 2020

1 reference

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

31 March 2020

1 reference

Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma

31 March 2020

1 reference

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

31 March 2020

1 reference

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

31 March 2020

1 reference

BRAF mutations in hairy-cell leukemia

31 March 2020

1 reference

High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.

31 March 2020

1 reference

Epigenomics: beyond CpG islands.

31 March 2020

1 reference

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

31 March 2020

1 reference

Linking DNA methylation and histone modification: patterns and paradigms

31 March 2020

1 reference

A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome

31 March 2020

1 reference

Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity

31 March 2020

1 reference

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

31 March 2020

1 reference

NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming

31 March 2020

1 reference

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

31 March 2020

1 reference

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

31 March 2020

1 reference

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

31 March 2020

1 reference

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

31 March 2020

1 reference

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

31 March 2020

1 reference

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

31 March 2020

1 reference

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

31 March 2020

1 reference

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

31 March 2020

1 reference

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

31 March 2020

1 reference

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

31 March 2020

1 reference

Deregulated microRNAs in multiple myeloma

31 March 2020

1 reference

Widespread microRNA repression by Myc contributes to tumorigenesis

31 March 2020

1 reference

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

31 March 2020

1 reference

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

31 March 2020

1 reference

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

31 March 2020

1 reference

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

31 March 2020

1 reference

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

31 March 2020

1 reference

A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.

31 March 2020

1 reference

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

31 March 2020

1 reference

Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes

31 March 2020

1 reference

31 March 2020

1 reference

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

31 March 2020

1 reference

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

31 March 2020

1 reference

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

31 March 2020

1 reference

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

31 March 2020

1 reference

Prognostic significance of copy-number alterations in multiple myeloma

31 March 2020

1 reference

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

31 March 2020

1 reference

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

31 March 2020

1 reference

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

31 March 2020

1 reference

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

31 March 2020

1 reference

Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development

31 March 2020

1 reference

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

31 March 2020

1 reference

Genetic events in the pathogenesis of multiple myeloma

31 March 2020

1 reference

The molecular classification of multiple myeloma

31 March 2020

1 reference

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

31 March 2020

1 reference

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

31 March 2020

1 reference

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

31 March 2020

1 reference

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

31 March 2020

1 reference

Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells

31 March 2020

1 reference

BCL6 represses NFκB activity in diffuse large B-cell lymphomas

31 March 2020

1 reference

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells

31 March 2020

1 reference

12 December 2020

DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes

1 reference

12 December 2020

VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene

1 reference

12 December 2020

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

1 reference

12 December 2020

Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

New Insights into Therapeutic Targets in Myeloma

1 reference

12 December 2020

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines

1 reference

12 December 2020

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1 reference

12 December 2020

Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.

1 reference

12 December 2020

Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance.

1 reference

12 December 2020

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

1 reference

12 December 2020